The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010
Open accessAbstract
IMPORTANCE: Opioid analgesic overdose mortality continues to rise in the United States, driven by increases in prescribing for chronic pain. Because chronic pain is a major indication for medical cannabis, laws that establish access to medical cannabis may change overdose mortality related to opioid analgesics in states that have enacted them. OBJECTIVE: To determine the association between the presence of state medical cannabis laws and opioid analgesic overdose mortality. DESIGN, SETTING, AND PARTICIPANTS: A time-series analysis was conducted of medical cannabis laws and state-level death certificate data in the United States from 1999 to 2010; all 50 states were included. EXPOSURES: Presence of a law establishing a medical cannabis program in the state. MAIN OUTCOMES AND MEASURES: Age-adjusted opioid analgesic overdose death rate per 100 000 population in each state. Regression models were developed including state and year fixed effects, the presence of 3 different policies regarding opioid analgesics, and the state-specific unemployment rate. RESULTS: Three states (California, Oregon, and Washington) had medical cannabis laws effective prior to 1999. Ten states (Alaska, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Mexico, Rhode Island, and Vermont) enacted medical cannabis laws between 1999 and 2010. States with medical cannabis laws had a 24.8% lower mean annual opioid overdose mortality rate (95% CI, -37.5% to -9.5%; P = .003) compared with states without medical cannabis laws. Examination of the association between medical cannabis laws and opioid analgesic overdose mortality in each year after implementation of the law showed that such laws were associated with a lower rate of overdose mortality that generally strengthened over time: year 1 (-19.9%; 95% CI, -30.6% to -7.7%; P = .002), year 2 (-25.2%; 95% CI, -40.6% to -5.9%; P = .01), year 3 (-23.6%; 95% CI, -41.1% to -1.0%; P = .04), year 4 (-20.2%; 95% CI, -33.6% to -4.0%; P = .02), year 5 (-33.7%; 95% CI, -50.9% to -10.4%; P = .008), and year 6 (-33.3%; 95% CI, -44.7% to -19.6%; P < .001). In secondary analyses, the findings remained similar. CONCLUSIONS AND RELEVANCE: Medical cannabis laws are associated with significantly lower state-level opioid overdose mortality rates. Further investigation is required to determine how medical cannabis laws may interact with policies aimed at preventing opioid analgesic overdose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse health effects of marijuana use.
Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. B. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1402309 · Cited by 2,774
The Economic Costs of Pain in the United States
Gaskin, D. J., & Richard, P. (2012) · The Journal of Pain · doi:10.1016/j.jpain.2012.03.009 · Cited by 2,359
Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008.
Paulozzi, L. J., Jones, C. M., Mack, K. A., & Rudd, R. A. (2011) · PubMed · Cited by 1,529
Association Between Opioid Prescribing Patterns and Opioid Overdose-Related Deaths
Bohnert, A. S. B. (2011) · JAMA · doi:10.1001/jama.2011.370 · Cited by 1,509
Opioid Prescriptions for Chronic Pain and Overdose: A Cohort Study
Dunn, K. M., Saunders, K. W., Rutter, C. M., Banta-Green, C. J., Merrill, J. O., Sullivan, M. D., Weisner, C. M., Silverberg, M. J., Campbell, C. I., Psaty, B. M., et al. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-2-201001190-00006 · Cited by 1,255
Tanda, G., Pontieri, F. E., & Chiara, G. D. (1997) · Science · doi:10.1126/science.276.5321.2048 · Cited by 1,080
Pharmacology and effects of cannabis: A brief review
Ashton, C. H. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.2.101 · Cited by 934
Pharmaceutical Overdose Deaths, United States, 2010
Jones, C. M., Mack, K. A., & Paulozzi, L. J. (2013) · JAMA · doi:10.1001/jama.2013.272 · Cited by 678
Escalation of Drug Use in Early-Onset Cannabis Users vs Co-twin Controls
Lynskey, M. T., Heath, A. C., Bucholz, K. K., Slutske, W. S., Madden, P. A. F., Nelson, E. C., Statham, D. J., & Martin, N. G. (2003) · JAMA · doi:10.1001/jama.289.4.427 · Cited by 649
Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008.
(2011) · PubMed · Cited by 640
Cited by
Designing Difference in Difference Studies: Best Practices for Public Health Policy Research
Wing, C., Simon, K., & Bello-Gomez, R. A. (2018) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-040617-013507 · Cited by 1,470
Practical considerations in medical cannabis administration and dosing
MacCallum, C. A., & Russo, E. B. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.004 · Cited by 663
Public health and international drug policy
Csete, J., Kamarulzaman, A., Kazatchkine, M., Altice, F., Balicki, M., Buxton, J., Cepeda, J., Comfort, M., Goosby, E., Goulão, J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00619-x · Cited by 641
Prevention and Treatment of Opioid Misuse and Addiction: A Review
Volkow, N. D., Jones, E. B., Einstein, E. B., & Wargo, E. M. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3126 · Cited by 596
US epidemiology of cannabis use and associated problems
Hasin, D. S. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.198 · Cited by 578
Humphreys, K., Shover, C. L., Andrews, C. M., Bohnert, A. S. B., Brandeau, M. L., Caulkins, J. P., Chen, J. H., Cuéllar, M.-F., Hurd, Y. L., Juurlink, D. N., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02252-2 · Cited by 421
Boehnke, K. F., Litinas, E., & Clauw, D. J. (2016) · The Journal of Pain · doi:10.1016/j.jpain.2016.03.002 · Cited by 412
Wen, H., Hockenberry, J. M., & Cummings, J. R. (2015) · Journal of Health Economics · doi:10.1016/j.jhealeco.2015.03.007 · Cited by 379
Evaluating the public health impacts of legalizing recreational cannabis use in the United States
Hall, W., & Lynskey, M. (2016) · Addiction · doi:10.1111/add.13428 · Cited by 357
Do medical marijuana laws reduce addictions and deaths related to pain killers?
Powell, D., Pacula, R. L., & Jacobson, M. (2018) · Journal of Health Economics · doi:10.1016/j.jhealeco.2017.12.007 · Cited by 345
Smart, R., & Pacula, R. L. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2019.1669626 · Cited by 305
Patrick, S. W., Fry, C. E., Jones, T. F., & Buntin, M. B. (2016) · Health Affairs · doi:10.1377/hlthaff.2015.1496 · Cited by 299
Altekruse, S. F., Cosgrove, C. M., Altekruse, W. C., Jenkins, R. A., & Blanco, C. (2020) · PLOS ONE · doi:10.1371/journal.pone.0227966 · Cited by 291
Medical Marijuana and Marijuana Legalization
Pacula, R. L., & Smart, R. (2017) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032816-045128 · Cited by 284
Cannabis and Pain: A Clinical Review
Hill, K. P., Palastro, M. D., Johnson, B., & Ditre, J. W. (2017) · Cannabis and Cannabinoid Research · doi:10.1089/can.2017.0017 · Cited by 281
Lucas, P., & Walsh, Z. (2017) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2017.01.011 · Cited by 271
Bradford, A. C., Bradford, W. D., Abraham, A., & Bagwell Adams, G. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.0266 · Cited by 269
Haroutounian, S., Ratz, Y., Ginosar, Y., Furmanov, K., Saifi, F., Meidan, R., & Davidson, E. (2016) · The Clinical Journal of Pain · doi:10.1097/ajp.0000000000000364 · Cited by 234
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
“…decrease in average opioid overdose mortalities from 1999 to 2010 as compared to states without medical cannabis access, consistent with data on efficacy of cannabinoids for treating pain, and suggesting a potential role for cannabis as a means of reducing opioid abuse (Bachhuber et al., 2014).”
BackgroundMorgan, J. R., Schackman, B. R., Weinstein, Z. M., Walley, A. Y., & Linas, B. P. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.02.031 · Cited by 159
Vigil, J. M., Stith, S. S., Adams, I. M., & Reeve, A. P. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187795 · Cited by 143
Recreational Cannabis Legalization and Opioid-Related Deaths in Colorado, 2000–2015
Livingston, M. D., Barnett, T. E., Delcher, C., & Wagenaar, A. C. (2017) · American Journal of Public Health · doi:10.2105/ajph.2017.304059 · Cited by 136
Marijuana and acute health care contacts in Colorado
Wang, G. S., Hall, K., Vigil, D., Banerji, S., Monte, A., & VanDyke, M. (2017) · Preventive Medicine · doi:10.1016/j.ypmed.2017.03.022 · Cited by 77
Scheim, A. I., Maghsoudi, N., Marshall, Z., Churchill, S., Ziegler, C., & Werb, D. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-035148 · Cited by 63
Campbell, C. I., Bahorik, A. L., VanVeldhuisen, P., Weisner, C., Rubinstein, A. L., & Ray, G. T. (2018) · Preventive Medicine · doi:10.1016/j.ypmed.2018.01.019 · Cited by 63
Freisthler, B., Gruenewald, P. J., & Wolf, J. P. (2015) · Child Abuse & Neglect · doi:10.1016/j.chiabu.2015.07.008 · Cited by 58
Hollingsworth, A., & Wing, C. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3592088 · Cited by 53
Bellnier, T., Brown, G. W., & Ortega, T. R. (2018) · Mental Health Clinician · doi:10.9740/mhc.2018.05.110 · Cited by 48
“Delta-9-tetrahydrocannabinol, the primary psychoactive cannabinoid, acts as a partial agonist with high-affinity at 2 G-protein coupled receptors: cannabinoid receptors 1 and 2 (CB1 and CB2).19 Cannabidiol receptors are found in high concentrations in areas of the brain that modulate nociceptive pain in similar amount…”
BackgroundInfluentialLeung, J., Chiu, V., Chan, G. C. K., Stjepanović, D., & Hall, W. D. (2019) · Current Addiction Reports · doi:10.1007/s40429-019-00291-x · Cited by 45
Marijuana legalization and opioid deaths.
Mathur, N. K., & Ruhm, C. J. (2023) · Journal of Health Economics · doi:10.1016/j.jhealeco.2023.102728 · Cited by 39
Recreational Cannabis Use Before and After Legalization in Women With Pelvic Pain
Geoffrion, R., Yang, E. C., Koenig, N. A., Brotto, L. A., Barr, A. M., Lee, T., Allaire, C., Bedaiwy, M. A., & Yong, P. J. (2021) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000004207 · Cited by 21
Dranitsaris, G., DeAngelis, C., Pearson, B., McDermott, L., & Pohlmann-Eden, B. (2021) · Applied Health Economics and Health Policy · doi:10.1007/s40258-021-00638-4 · Cited by 10
De Aquino, J. P., Sofuoglu, M., Stefanovics, E. A., & Rosenheck, R. A. (2020) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2020.1818248 · Cited by 6
Metadata
- Authors
- Bachhuber, M. A., Saloner, B., Cunningham, C. O., & Barry, C. L.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2014-10-01
- Volume
- 174
- Issue
- 10
- Pages
- 1668
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W2123439904
- Cited by
- 695
- References
- 31
- FWCI
- 49.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.